Health economist underwhelmed by Budget 2024

Image of Paula Lorgelly, Health Economist

30 May 2024

NZ Doctor.

Health economist Paula Lorgelly says many Kiwis who were expecting more funding for new cancer drugs and for Pharmac will be sadly disappointed by Budget 2024, which she sees as underwhelming.

Read more

Other stories

Academic LiteratureDrugs, devices and diagnostics
exploratory research in clinical and social pharmacy cover
Lived experience of affordability as a barrier to prescription medicines: A longitudinal qualitative study

Lived experience of affordability as a barrier to prescription medicines: A longitudinal qualitative study

Exploring lived experience provides insights into the multiple ways that lack of affordability prevents access to medicines: directly, through interaction with other barriers to access including transport, by damaging trust and reducing acceptability of services, and by making participants less able to deal with mistakes made by health professionals.

Key issues

HEALTH SERVICES AND SYSTEMS

Covering developments in the provision, funding and organisation of health care services.

EQUITY

Exploring the impacts of the health system on minorities within the population, notably including Māori, Pacifica, Asians and LGBTQI.

DRUGS, DEVICE AND DIAGNOSTICS

Covering prescription medicines and medical devices.

PUBLIC HEALTH

Focusing on efforts to promote health and prevent disease through social and economic interventions.

DIGITAL HEALTH

Exploring the potential digital transformation to provide a more connected and accessible health system.

TE TIRITI

Monitoring how the health reforms and the performance of the health sector uphold Te Tiriti obligations.